Matthew P Goetz Selected Research

Fulvestrant (Faslodex)

1/2023	Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial.
1/2022	The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer.
4/2021	Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.
1/2021	Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
1/2021	Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models.
1/2021	Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
1/2020	Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.
1/2020	Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.
4/2018	Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.
11/2017	MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew P Goetz Research Topics

Disease

164	Breast Neoplasms (Breast Cancer) 05/2024 - 12/2005
112	Neoplasms (Cancer) 03/2024 - 10/2003
25	Triple Negative Breast Neoplasms 01/2024 - 02/2014
13	Neoplasm Metastasis (Metastasis) 08/2021 - 07/2002
9	Pathologic Complete Response 11/2023 - 01/2015
6	Neutropenia 01/2023 - 06/2017
6	Pain (Aches) 03/2013 - 07/2002
5	Disease Progression 06/2021 - 06/2017
5	Colorectal Neoplasms (Colorectal Cancer) 01/2013 - 06/2004
3	Leukopenia 01/2023 - 11/2017
3	Diarrhea 01/2022 - 11/2017
2	Ductal Carcinoma 07/2023 - 03/2023
2	Lymphoma (Lymphomas) 01/2023 - 03/2016
2	Anemia 01/2023 - 02/2005
2	Residual Neoplasm 01/2022 - 01/2022
2	Brain Neoplasms (Brain Tumor) 01/2022 - 12/2021
2	Aggressive Fibromatosis (Desmoid) 12/2021 - 02/2021
2	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 01/2018
2	Endometrial Neoplasms (Endometrial Cancer) 10/2017 - 12/2014
2	Nausea 08/2017 - 02/2005

Drug/Important Bio-Agent (IBA)

43	Estrogen ReceptorsIBA 01/2024 - 04/2006
38	Hormones (Hormone)IBA 04/2024 - 10/2009
37	Tamoxifen FDA LinkGeneric 10/2023 - 12/2005
22	4-hydroxy-N-desmethyltamoxifenIBA 12/2023 - 12/2005
21	Aromatase InhibitorsIBA 01/2023 - 04/2010
17	ErbB Receptors (EGF Receptor)IBA 01/2024 - 04/2008
16	Estrogens (Estrogen)FDA Link 05/2024 - 03/2009
16	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 01/2023 - 12/2005
15	Anastrozole (Arimidex)FDA LinkGeneric 05/2024 - 04/2010
15	abemaciclibIBA 04/2024 - 11/2017
15	Biomarkers (Surrogate Marker)IBA 03/2024 - 01/2005
14	Phenobarbital (Luminal)FDA Link 04/2024 - 03/2012
13	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 10/2009
10	human ERBB2 proteinIBA 01/2023 - 01/2010
10	Fulvestrant (Faslodex)FDA Link 01/2023 - 11/2017
9	Progesterone Receptors (Progesterone Receptor)IBA 01/2024 - 12/2014
9	exemestane (Aromasin)FDA Link 01/2023 - 12/2016
8	Trastuzumab (Herceptin)FDA Link 01/2023 - 05/2013
8	Letrozole (Femara)FDA LinkGeneric 01/2022 - 05/2013
7	Proteins (Proteins, Gene)FDA Link 01/2023 - 02/2012
6	Selective Estrogen Receptor Modulators (SERM)IBA 10/2017 - 11/2011
6	Oxaliplatin (Eloxatin)FDA LinkGeneric 09/2017 - 10/2003
6	Irinotecan (Camptosar)FDA LinkGeneric 09/2017 - 10/2003
5	Estradiol (Delestrogen)FDA LinkGeneric 05/2024 - 04/2013
5	AnthracyclinesIBA 01/2023 - 12/2017
5	Lapatinib (GW572016)FDA Link 01/2023 - 05/2013
5	Androgen Receptors (Androgen Receptor)IBA 01/2023 - 02/2014
5	EnzymesIBA 01/2019 - 01/2007
5	Estrogen Receptor alphaIBA 11/2017 - 03/2009
4	Cyclin-Dependent Kinase 4IBA 05/2024 - 11/2017
4	Estrogen Receptor betaIBA 01/2023 - 03/2011
4	taxaneIBA 12/2022 - 12/2017
4	Fluorouracil (Carac)FDA LinkGeneric 09/2017 - 10/2003
4	ParaffinIBA 12/2014 - 12/2005
3	Estrone FDA Link 05/2024 - 07/2017
3	Aurora Kinase AIBA 01/2023 - 04/2018
3	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2023 - 11/2017
3	RNA (Ribonucleic Acid)IBA 10/2021 - 01/2017
3	Capecitabine (Xeloda)FDA Link 07/2021 - 06/2004
3	Aromatase (CYP19)IBA 01/2020 - 04/2013
3	P-2 (P 2)IBA 01/2017 - 07/2013
3	Raloxifene Hydrochloride (Evista)FDA Link 01/2015 - 11/2011
3	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 01/2013 - 12/2005
3	Analgesics (Analgesic Drugs)IBA 08/2011 - 07/2002
2	LigandsIBA 01/2024 - 01/2020
2	Circulating Tumor DNAIBA 10/2023 - 10/2017
2	MLN 8237IBA 01/2023 - 04/2018
2	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2023 - 03/2009
2	Everolimus FDA Link 01/2023 - 01/2020
2	VaccinesIBA 09/2022 - 12/2021
2	neratinibIBA 01/2022 - 10/2017
2	InterferonsIBA 10/2021 - 01/2021
2	Phosphotransferases (Kinase)IBA 01/2021 - 12/2018
2	Gonadotropin-Releasing Hormone (GnRH)FDA Link 01/2021 - 05/2013
2	Tyrosine (L-Tyrosine)FDA Link 01/2021 - 12/2018
2	AntibodiesIBA 01/2020 - 02/2012
2	Long Noncoding RNAIBA 01/2019 - 12/2016
2	olaparibIBA 12/2018 - 01/2017
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 05/2018 - 08/2017
2	Vorinostat FDA Link 01/2018 - 01/2015
2	Cytochrome P-450 CYP2D6 InhibitorsIBA 01/2018 - 11/2011
2	Carboplatin (JM8)FDA LinkGeneric 08/2017 - 01/2015
2	Paclitaxel (Taxol)FDA LinkGeneric 06/2017 - 08/2010
2	Histone Deacetylase InhibitorsIBA 04/2016 - 01/2015
2	Formaldehyde (Formol)FDA Link 12/2014 - 12/2014
2	afimoxifene (hydroxytamoxifen)IBA 10/2009 - 03/2009
2	Interleukin-17 (Interleukin 17)IBA 09/2008 - 04/2006
2	Leucovorin (Folinic Acid)FDA Link 05/2007 - 10/2003

Therapy/Procedure

92	Therapeutics 03/2024 - 01/2005
39	Drug Therapy (Chemotherapy) 01/2024 - 07/2002
22	Neoadjuvant Therapy 01/2024 - 05/2015
9	Radiotherapy 01/2024 - 07/2002
9	Adjuvant Chemotherapy 02/2021 - 05/2006
4	Cryosurgery 03/2013 - 01/2006
4	Radiofrequency Ablation 08/2011 - 07/2002
3	Chemoprevention 01/2020 - 11/2011
3	Aftercare (After-Treatment) 03/2013 - 07/2002
2	Mastectomy (Mammectomy) 07/2023 - 03/2023
2	Segmental Mastectomy (Lumpectomy) 07/2023 - 03/2023
2	Immunotherapy 01/2021 - 08/2020